Division of Hand Surgery, Department of Orthopaedic Surgery, Duke University School of Medicine, Durham, NC.
Division of Plastic and Reconstructive Surgery, Department of Surgery, University of Missouri, Columbia, MO.
J Hand Surg Am. 2024 Jun;49(6):511-525. doi: 10.1016/j.jhsa.2024.02.001. Epub 2024 Mar 26.
As osteoarthritis (OA) of the trapeziometacarpal (TMC) joint leads to a high degree of disease burden with compromises in rudimentary and fine movements of the hand, intra-articular injections may be a desirable treatment option. However, because there are no evidence-based guidelines, the choice of intra-articular injection type is left to the discretion of the individual surgeon in collaboration with the patient. The purpose of our study was to perform a systematic review and meta-analysis using level I studies to compare outcomes following corticosteroid and alternative methods of intra-articular injections for the management of TMC OA. Our hypothesis was that intra-articular corticosteroid injections were no more effective than other methods of intra-articular injections for the management of TMC OA.
A systematic literature search was performed. Eligible for inclusion were randomized control trials reporting on intra-articular corticosteroid injection for the management of TMC OA. Clinical outcomes were recorded.
The 10 included studies comprised 673 patients. The mean age was 57.8 ± 8.3 years, with a mean follow-up of 6.4 ± 2.7 months. There was no significant difference in visual analog scale scores, grip strength and tip pinch strength between corticosteroids and hyaluronic acid at short- and medium-term follow-up. Further, there was no difference in visual analog scale pain scores at rest at medium-term follow-up between corticosteroids and platelet-rich plasma.
Despite short-term improvement with intra-articular corticosteroid injections, there was no significant difference in pain and functional outcomes following intra-articular corticosteroid injections compared to hyaluronic acid or platelet-rich plasma administration. Given the affordability, ease of administration, and efficacy associated with corticosteroids, they are a favorable option when considering the choice of intra-articular injection for the management of TMC OA.
TYPE OF STUDY/LEVEL OF EVIDENCE: Therapeutic II.
由于腕掌关节(TMC)的骨关节炎(OA)导致手部基本和精细运动受损,从而带来高度的疾病负担,关节内注射可能是一种理想的治疗选择。然而,由于缺乏循证指南,关节内注射类型的选择取决于个别外科医生与患者合作的判断。我们的研究目的是使用一级研究进行系统评价和荟萃分析,比较 TMC OA 管理中皮质类固醇和替代关节内注射类型的结果。我们的假设是,关节内皮质类固醇注射在 TMC OA 的管理中并不比其他关节内注射方法更有效。
进行了系统的文献检索。纳入的随机对照试验报告了皮质类固醇关节内注射治疗 TMC OA。记录临床结果。
纳入的 10 项研究共纳入 673 例患者。平均年龄为 57.8 ± 8.3 岁,平均随访时间为 6.4 ± 2.7 个月。在短期和中期随访中,皮质类固醇和透明质酸之间在视觉模拟评分、握力和指尖捏力方面没有显著差异。此外,在中期随访中,皮质类固醇和富血小板血浆之间在休息时的视觉模拟评分疼痛方面也没有差异。
尽管关节内皮质类固醇注射有短期改善,但与透明质酸或富血小板血浆给药相比,关节内皮质类固醇注射在疼痛和功能结果方面没有显著差异。鉴于皮质类固醇的可负担性、易于管理和疗效,当考虑选择关节内注射治疗 TMC OA 时,它们是一种有利的选择。
研究类型/证据水平:治疗性 II 级。